AcelRx Marches Toward NDA Filing For Pain Drug-Device
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The specialty pharma is planning to file an NDA in the third quarter for its sublingual sufentanil NanoTab system for pain after the first of two pivotal trials reads out positively.